CADL
Candel Therapeutics, Inc.Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-07-06 | Sims Mark E. |
Chief Commercial Officer |
Other↑
|
No Securities Owned
|
0 |
| 2026-07-06 | Sims Mark E. |
Chief Commercial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
25% of the shares underlying this option shall vest and become exercisable on July 6, 2027, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |
Stock Option (Right to Buy)
|
285,000 |
| 2026-06-30 | PAPA JOSEPH C |
Director, President and CEO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant. |
Stock Option (Right to Buy)
|
1,331 |
| 2026-06-30 | Loggia Nicoletta |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant. |
Stock Option (Right to Buy)
|
381 |
| 2026-06-30 | Manning Paul B |
10% Owner |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant. |
Stock Option (Right to Buy)
|
2,199 |
| 2026-06-29 | Tyagarajan Seshu |
Chief Technology Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 3/16/2026. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.07 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 herein. |
Common Stock
|
7,000 |
| 2026-06-29 | Barone Francesca |
Chief Scientific Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 3/16/2026. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 herein. |
Common Stock
|
23,447 |
| 2026-06-23 | Nabel Gary J. |
Director, Chief Innovation Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. |
Stock Option (Right to Buy)
|
32,000 |
| 2026-06-23 | Loggia Nicoletta |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. |
Stock Option (Right to Buy)
|
32,000 |
| 2026-06-23 | Manning Paul B |
10% Owner |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. |
Stock Option (Right to Buy)
|
32,000 |
| 2026-06-23 | Benz Edward J. JR |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. |
Stock Option (Right to Buy)
|
32,000 |
| 2026-06-23 | Martell Christopher |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. |
Stock Option (Right to Buy)
|
32,000 |
| 2026-06-23 | Radhakrishnan Maha |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. |
Stock Option (Right to Buy)
|
32,000 |
| 2026-06-23 | Gaeta Renee |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. |
Stock Option (Right to Buy)
|
32,000 |
| 2026-06-23 | Nguyen Diem |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. |
Stock Option (Right to Buy)
|
32,000 |
| 2026-06-23 | PAPA JOSEPH C |
Director, President and CEO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. |
Stock Option (Right to Buy)
|
32,000 |
| 2026-03-31 | Manning Paul B |
10% Owner |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant. |
Stock Option (Right to Buy)
|
4,618 |
| 2026-03-31 | Loggia Nicoletta |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant. |
Stock Option (Right to Buy)
|
779 |
| 2026-03-31 | PAPA JOSEPH C |
Director, President and CEO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant. |
Stock Option (Right to Buy)
|
2,795 |
| 2026-02-23 | Manning Paul B |
10% Owner |
Buy↑
Filing footnotes — Common Stock (Indirect)
The shares are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
Common Stock
(I)
|
550,458 |
| 2026-01-26 | Schoch Charles |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 26, 2026, subject to the Reporting Person's continued service on each vesting date. |
Stock Option (Right to Buy)
|
232,000 |
| 2026-01-26 | Barone Francesca |
Chief Scientific Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 26, 2026, subject to the Reporting Person's continued service on each vesting date. |
Stock Option (Right to Buy)
|
232,000 |
| 2026-01-26 | Nichols William Garrett |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 26, 2026, subject to the Reporting Person's continued service on each vesting date. |
Stock Option (Right to Buy)
|
136,500 |
| 2026-01-26 | Tyagarajan Seshu |
Chief Technology Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 26, 2026, subject to the Reporting Person's continued service on each vesting date. |
Stock Option (Right to Buy)
|
154,000 |
| 2026-01-26 | Tak Paul Peter |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 26, 2026, subject to the Reporting Person's continued service on each vesting date. |
Stock Option (Right to Buy)
|
629,000 |
| 2025-07-28 | Nichols William Garrett |
Chief Medical Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/22/2024. |
Common Stock
|
937 |
| 2025-07-28 | Nichols William Garrett |
Chief Medical Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/22/2024. |
Common Stock
|
937 |
| 2025-07-28 | Nichols William Garrett |
Chief Medical Officer |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/22/2024. This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following April 28, 2023, subject to the Reporting Person's continued service on each vesting date. |
Stock Option (Right to Buy)
|
937 |
| 2025-06-30 | Nichols William Garrett |
Chief Medical Officer |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/22/2024. This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following April 28, 2023, subject to the Reporting Person's continued service on each vesting date. |
Stock Option (Right to Buy)
|
781 |
| 2025-06-30 | Nichols William Garrett |
Chief Medical Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/22/2024. |
Common Stock
|
781 |
| 2025-06-30 | Nichols William Garrett |
Chief Medical Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/22/2024. |
Common Stock
|
781 |
| 2025-06-25 | Manning Paul B |
10% Owner |
Award↑
Filing footnotes — Common Stock (Indirect)
Represents shares acquired from the Issuer in a registered direct offering pursuant to the terms of a Securities Purchase Agreement dated as of June 23, 2025. The shares are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
Common Stock
(I)
|
1,070,663 |
| 2025-06-25 | Martell Christopher |
Director |
Award↑
Filing footnotes — Common Stock (Indirect)
Represents shares acquired from the Issuer in a registered direct offering pursuant to the terms of a Securities Purchase Agreement dated as of June 23, 2025. Shares held by Spouse. |
Common Stock
(I)
|
111,349 |
| 2025-06-25 | Nabel Gary J. |
Director, Chief Innovation Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares acquired from the Issuer in a registered direct offering pursuant to the terms of a Securities Purchase Agreement dated as of June 23, 2025. |
Common Stock
|
5,353 |
| 2025-06-25 | Tyagarajan Seshu |
Chief Technology Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares acquired from the Issuer in a registered direct offering pursuant to the terms of a Securities Purchase Agreement dated as of June 23, 2025. |
Common Stock
|
5,353 |
| 2025-06-25 | Schoch Charles |
Chief Financial Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares acquired from the Issuer in a registered direct offering pursuant to the terms of a Securities Purchase Agreement dated as of June 23, 2025. |
Common Stock
|
5,353 |
| 2025-06-25 | PAPA JOSEPH C |
Director, President and CEO |
Award↑
Filing footnotes — Common Stock (Indirect)
Represents shares acquired from the Issuer in a registered direct offering pursuant to the terms of a Securities Purchase Agreement dated as of June 23, 2025. Shares held by Joseph C. Papa Revocable Living Trust, which is wholly owned by a trust for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any. |
Common Stock
(I)
|
64,239 |
| 2025-06-25 | Loggia Nicoletta |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares acquired from the Issuer in a registered direct offering pursuant to the terms of a Securities Purchase Agreement dated as of June 23, 2025. |
Common Stock
|
2,141 |
| 2025-06-25 | Barone Francesca |
Chief Scientific Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares acquired from the Issuer in a registered direct offering pursuant to the terms of a Securities Purchase Agreement dated as of June 23, 2025. |
Common Stock
|
4,282 |
| 2025-06-25 | Tak Paul Peter |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares acquired from the Issuer in a registered direct offering pursuant to the terms of a Securities Purchase Agreement dated as of June 23, 2025. |
Common Stock
|
42,826 |
| 2025-06-20 | Schoch Charles |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option is subject to time-based vesting. 25% of the shares underlying this option shall vest and become exercisable on June 20, 2026, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |
Stock Option (Right to Buy)
|
50,000 |
| 2025-06-17 | Gaeta Renee |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 17, 2026 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. |
Stock Option (Right to Buy)
|
14,240 |
| 2025-06-17 | Benz Edward J. JR |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 17, 2026 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. |
Stock Option (Right to Buy)
|
14,240 |
| 2025-06-17 | Loggia Nicoletta |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 17, 2026 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. |
Stock Option (Right to Buy)
|
14,240 |
| 2025-06-17 | PAPA JOSEPH C |
Director, President and CEO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 17, 2026 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. |
Stock Option (Right to Buy)
|
14,240 |
| 2025-06-17 | Martell Christopher |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 17, 2026 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. |
Stock Option (Right to Buy)
|
14,240 |
| 2025-06-17 | Manning Paul B |
10% Owner |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 17, 2026 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. |
Stock Option (Right to Buy)
|
14,240 |
| 2025-06-17 | Nabel Gary J. |
Director, Chief Innovation Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 17, 2026 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. |
Stock Option (Right to Buy)
|
14,240 |
| 2025-06-17 | Nguyen Diem |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 17, 2026 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. |
Stock Option (Right to Buy)
|
14,240 |
| 2025-06-04 | Radhakrishnan Maha |
Director |
Other↑
|
No Securities Owned
|
0 |